Non alcoholic Steatohepatitis (Nash) Market Set To Grow To Over $900m In 2017

06 August 2017
Pharma

Visiongain has launched a new pharma report Nonalcoholic Steatohepatitis (NASH) Market Report to 2027: Forecasts and Analysis by Therapeutics (GFT 505, Obeticholic Acid (INT-747), Simtuzumab and Liraglutide (Victoza), Vitamin E, Pioglitazone, Placebo) and Region

Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a build up of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Usually, nonalcoholic steatohepatitis (NASH) are silent diseases with few or no symptoms. There may not be any symptoms even if there is any development of cirrhosis due to NASH. The minor symptoms may include discomfort in the upper right side of the abdomen.

The lead Visiongain report analyst for this report commented; “Nonalcoholic Steatohepatitis (NASH) also known as “silent disease” is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are found among all demographics (from children to adults); however, they are more prevalent in younger people. Corner stage of cirrhosis is a form of NASH that can be reversed with proper medication. This has led to an increase in the number of incidences and the severity of the disease. Additionally, the absence of efficient diagnostic technologies acts as a major hurdle for the research of NASH therapeutics.

Nevertheless, the emergence of novel biomarker technologies and improvements in liver biopsy technologies are expected to bring about an evolution in the diagnosis of NASH and other fatty liver diseases.”

The Global market is highly competitive with many different players entering the market. The report discusses products from leading companies in the market. Notable companies in the NASH market include AstraZeneca, Intercept Pharmaceuticals, Inc., GENFIT SA, Gilead Sciences, Inc., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb, Galmed Pharmaceuticals Ltd., Immuron Limited and Novo Nordisk AG amongst others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever